Alimera Sciences launches ILUVIEN in Germany
Alimera Sciences announces that it will immediately commence the launch of ILUVIEN in Germany for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. Following the European Union's Mutual Recognition Procedure in March 2019, Germany is the second country in Europe in which ILUVIEN is now commercially available to be prescribed to patients suffering from NIPU, a disease with no sustained treatment options. In June 2019, Alimera announced a positive recommendation by the National Institute for Health and Care Excellence, facilitating launch of the NIPU indication in the United Kingdom. Launch of the NIPU indication follows the establishment of national pricing and receipt of the required regulatory approval by the Federal Institute for Drugs and Medical Devices, the medical regulatory authority in Germany. Germany is Alimera's largest direct market in Europe based on current sales for ILUVIEN's diabetic macular edema indication, and it is estimated that the number of patients diagnosed with NIPU is approximately 15-20% of the DME patient population.